| Title |
The preventive effect on respiratory tract infections of Oscillococcinum®. A cost-effectiveness analysis
|
|---|---|
| Published in |
ClinicoEconomics and Outcomes Research: CEOR, January 2018
|
| DOI | 10.2147/ceor.s144300 |
| Pubmed ID | |
| Authors |
Giorgio L Colombo, Sergio Di Matteo, Chiara Martinotti, Martina Oselin, Giacomo M Bruno, Gianfranco M Beghi |
| Abstract |
Anas barbariae hepatis et cordis extractum 200K (Oscillococcinum®) is used to treat and prevent seasonal colds and airway inflammatory affections, improve symptom control, and reduce the frequency of respiratory tract infection (RTI) episodes. The objective of this controlled observational study is to investigate, from the Italian National Health Service (NHS) point of view, the role of Anas barbariae hepatis et cordis extractum 200K in preventing RTIs and estimate the annual average cost per patient due to visits and medicines in a real-world setting, investigating whether this method of treatment can bring savings for the NHS. Data from a single center from 2002 to 2011 were used. The analysis examined 455 patients who suffered from respiratory diseases. Of the total number of patients, 246 were treated with Anas barbariae hepatis et cordis extractum 200K while 209 were not treated (Control group). All the data concerning RTI episodes, pharmacological treatments, and pneumological visits were extracted from the database. It was found that, regardless of the diagnosis, the frequency of RTI episodes was always lower in patients treated with Anas barbariae hepatis et cordis extractum 200K; the difference between the numbers of events occurring was statistically significant in every class of patients (p<0.001). The costs that the NHS had to incur were significantly lower in the classes of patients treated (p<0.001). The results indicate that Anas barbariae hepatis et cordis extractum 200K has a preventive effect on the onset of RTI episodes. The analysis shows that treating patients with Anas barbariae hepatis et cordis extractum 200K lowers costs for the NHS; this is primarily due to the fact that the medication causes fewer episodes of RTI to develop. This study suggests that the treatment with Anas barbariae hepatis et cordis extractum 200K could be helpful in preventing RTIs and improving the health status of patients who suffer from respiratory diseases, and it could lead to savings to the Italian NHS. |
X Demographics
The data shown below were collected from the profiles of 15 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 4 | 27% |
| Netherlands | 1 | 7% |
| Italy | 1 | 7% |
| Unknown | 9 | 60% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 15 | 100% |
Mendeley readers
The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 24 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 5 | 21% |
| Other | 3 | 13% |
| Student > Ph. D. Student | 3 | 13% |
| Researcher | 2 | 8% |
| Professor | 1 | 4% |
| Other | 1 | 4% |
| Unknown | 9 | 38% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 5 | 21% |
| Pharmacology, Toxicology and Pharmaceutical Science | 2 | 8% |
| Nursing and Health Professions | 2 | 8% |
| Biochemistry, Genetics and Molecular Biology | 1 | 4% |
| Business, Management and Accounting | 1 | 4% |
| Other | 2 | 8% |
| Unknown | 11 | 46% |
Attention Score in Context
This research output has an Altmetric Attention Score of 33. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 October 2023.
All research outputs
#1,206,547
of 25,461,852 outputs
Outputs from ClinicoEconomics and Outcomes Research: CEOR
#31
of 525 outputs
Outputs of similar age
#27,517
of 450,092 outputs
Outputs of similar age from ClinicoEconomics and Outcomes Research: CEOR
#2
of 9 outputs
Altmetric has tracked 25,461,852 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 95th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 525 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 12.0. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 450,092 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 93% of its contemporaries.
We're also able to compare this research output to 9 others from the same source and published within six weeks on either side of this one. This one has scored higher than 7 of them.